Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women’s risk of acquiring HIV by 39 percent overall and asks follow-up questions. What additional trials are being considered and why? Who will map the next steps? This issue also touches on the increasing discussions of “treatment as prevention” in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.
Px Wire October-December 2010, Vol. 3, No. 4
Comment Letter to Ambassador Goosby on Draft PEPFAR Country Operational Plan for Zimbabwe
A 4-page response letter developed by a coalition of civil society groups summarizing concerns and demands related to the US PEPFAR program’s 2012 Country Operating Plan. A country operating plan dictates the scope, funding levels and targets of PEPFAR programming on an annual basis.
Comment Letter to Ambassador Goosby on Draft PEPFAR Country Operational Plan for Zambia
This four-page letter on behalf of the civil society coalition in Zambia discusses recommendations for PEPFAR’s Country Operating Plan. The letter calls for stronger benchmarks and increased investment in several HIV prevention modalities.
HIV/AIDS in Uganda: 30 Years On! – A case for treatment as prevention approach
This report by 2012 AVAC Advocacy Fellow Alice Kayongo-Mutebi describes successes and challenges in a year-long campaign to expand access to antiretroviral treatment for HIV positive people in Uganda. It includes sections on the history of Uganda’s AIDS response, achievements in the work of a Ugandan civil society coalition seeking to improve ART access. It describes challenges and makes recommendations for future work.
Px Wire July-September 2010, Vol. 3, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews highlights from the biannual International Microbicides Conference (M2010) held in May, including discussions of the potential opportunities and challenges of ARV-based prevention in topical and oral forms, new developments in delivery systems for microbicides and increasing recognition of rectal microbicides as a key area for exploration. This issue also covers what to expect with the forthcoming results of CAPRISA 004.
Budgeting to End AIDS in Kenya: Accelerated ART Scale-Up is the Only Cost-Effective Option
This one-page draft issue brief illustrates the benefits of ART scale up on public health in Kenya. The report advocates for the commitment of reaching one million Kenyans by 2015 and shows the impact of this benchmark using CDC Kenya data.
We can use it if it’s made for us: Kenyan Sex workers perspectives and Voices on Microbicides and PrEP
This report gathers perceptions and concerns from female sex works in Kenya concerning access to microbicides and PrEP. It highlights the importance of engaging this key population in product research and development.
Px Wire July-September 2009, Vol. 2, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue is designed to provide background and perspectives on some of the key issues and questions that have emerged as work around understanding and interpreting the results of the Thai trial moves forward.
Px Wire April-June 2009, Vol. 2, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue features multiple trial updates, including a review of the key findings from a trial of HSV-2 suppression. The issue also features a discussion of the results of the HPTN 035 microbicide trial (which tested PRO 2000 and BufferGel) and preparations for the upcoming results of MDP 301, also testing PRO 2000 gel. Additionally, this issue provides information on new trials including HVTN 505 (described in this year’s first issue of Px Wire), which began screening participants in June, a new trial on intermittent PrEP scheduled to begin in July, and research to test a nipple shield to help prevent HIV transmission during breastfeeding.
Px Wire April-June 2014, Vol. 7, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people and also explores progress in implementing oral PrEP in the nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP.